Evivo study on atopic dermatitis reduction

Shared Hosting - from $2.88/mo

The study aims to investigate whether infant probiotic Evivo can reduce development of early childhood atopic dermatitis, which is implicated in asthma, allergic rhinitis and food allergies, and affects up to 20% of children.

The study will assess the effects of introducing a specific gut bacterium, Bifidobacterium longum​ subspecies infantis (activated B. infantis​ EVC001, marketed as Evivo) in inhibiting the onset of atopic dermatitis, the most prevalent pediatric skin disorder, in the first year of life.

The agreement was facilitated by Johnson & Johnson Innovation LLC.

“Atopic dermatitis is not just a debilitating condition for millions of children, but is also a gateway condition associated with numerous chronic conditions that carry a lifelong physical, emotional and financial burden,”​ said David Kyle, PhD, chairman of the board and chief scientific officer, Evolve BioSystems, Inc.

“This study looks to demonstrate whether the introduction of B. infantis EVC001 to the infant gut microbiome will deflect the development of atopic dermatitis and establish a path to lifelong health.”

Atopic dermatitis is an immunological disease condition that affects up to one in five children, with 60% of cases presenting by age one year.

Atopic dermatitis has been implicated in predisposing children to a range of pediatric health conditions ranging from food allergies to asthma. These individuals also have an increased risk of other conditions associated with inflammation, such as inflammatory bowel disease and rheumatoid arthritis, and are at increased risk of attention deficit/hyperactivity disorder and depression.

Source link

Shared Hosting - from $2.88/mo


Please enter your comment!
Please enter your name here